ClinicalTrials.gg
TerminatedNCT04732286Updated May 8, 2025Results posted

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

A Phase 3 interventional study of Atezolizumab and Bevacizumab in Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche. Terminated at 25 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was completed as pre-specified in the protocol. Study was terminated only for participants who were in the study even after 24 months of follow-up as specified in the protocol.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Enrollment
15th of 41
100 · median 40
Started
2021
with 8 others
Phase 3
11 of 41
2 open now
Registered
13th of 41
by date
Lead sponsor
6 of 41
Hoffmann-La Roche

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 15th largest by enrollment, is one of 9 that started in 2021, is one of 11 in phase 3, and was the 13th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is a Phase IIIb, one arm, multicenter, open-label study primarily designed to evaluate the safety of atezolizumab + bevacizumab in participants with unresectable or unsuitable for locoregional treatments for metastatic HCC not previously treated with systemic therapy. As part of its secondary objectives, this study is also designed to evaluate the efficacy of atezolizumab and bevacizumab in these participants.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or and/or unresectable HCC with diagnosis confirmed by histology or radiologically, following the AASLD criteria
  • Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies
  • No prior systemic therapy (including systemic agents) for HCC
  • At least one measurable (per 1.1) untreated lesion detected by CT scan
  • Patients who received prior local therapy such as radiofrequency ablation, percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization (excluding transarterial radioembolization.) are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with RECIST version 1.1

Exclusion criteria

Exclusion Criteria:

  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Co-infection of and
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Arm A (atezolizumab plus bevacizumab)

    Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

    Drug: Atezolizumab · Drug: Bevacizumab

Interventions

  • Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.

    Also known as: Tecentriq

  • Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Discontinued Atezolizumab and/or Bevacizumab Due to Adverse Events (AE) of Grade ≥ 3

    AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The severity of AEs was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0) with the following grades: Grade 1 = asymptomatic or mild symptoms; Grade 2 = minimal, local, or non-invasive intervention indicated; Grade 3 = severe or medically significant, but not immediately life-threatening; Grade 4 = life-threatening consequences or urgent intervention indicated and Grade 5 = death related to AE.

    Time frame: From Cycle 1 Day 1 up to 30 days after the final dose of the study drug or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 32 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from initiation of study treatment to death from any cause. OS was analyzed using Kaplan-Meier (K-M) methods and Greenwood's formula. Any participant who did not die during the study was censored at the last known date to be alive.

    Time frame: Up to 35 months

  2. Progression-free Survival (PFS)

    PFS was defined as the time from initiation of study treatment to the first occurrence of disease progression (PD) or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1). PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm). PFS was analyzed using K-M methods and Greenwood's formula. Any participant who did not experience disease progression or death during the study and were censored at the last known date to be alive or without disease progression.

    Time frame: Up to 35 months

  3. Objective Response Rate (ORR)

    ORR = percentage of participants with a complete or partial response (CR or PR), on 2 consecutive investigator assessments ≥ 4 weeks apart in participants with measurable disease at baseline as determined by the investigator according to RECIST v1.1. CR = disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to \< 10 mm. PR = at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Participants without a post-baseline tumor assessment were considered non-responders. 95% confidence interval (CI) was derived using Wilson score intervals. Percentages have been rounded off.

    Time frame: Up to 35 months

  4. Time to Progression (TTP)

    TTP was defined as the time from initiation of study treatment to the first occurrence of PD, as determined by the investigator according to RECIST v1.1. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, SOD must also demonstrate an absolute increase of ≥ 5 mm. TTP was analyzed using K-M methods and Greenwood's formula. Any participant who had no disease progression was censored at the last known date without disease progression.

    Time frame: Up to 35 months

  5. Duration of Response (DOR)

    DOR was defined as the time from the first occurrence of a documented objective response (CR or PR) to PD or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. DOR was analyzed using K-M methods and Greenwood's formula. Any participant who did not experience disease progression or death during the study was censored at the last known date to be alive or without disease progression.

    Time frame: Up to 35 months

  6. Percentage of Participants Who Started Second-line Treatment

    Participants who started second-line of treatment were assessed. Percentages have been rounded off.

    Time frame: Up to 35 months

  7. Change From Baseline in International Normalized Ratio (INR)

    The INR is a standardized measure of the prothrombin time. Blood samples were collected from participants to evaluate coagulation parameters.

    Time frame: Baseline up to Cycle 42 (1 cycle = 21 days)

  8. Change From Baseline in Albumin-Bilirubin (ALBI) Score

    Blood samples were collected from participants to evaluate of ALBI grades. ALBI assessment grades of 1 to 3 was based on ALBI score calculation. ALBI score= log10 bilirubin (micromole per liter) \[μmol/L\] × 0.66 + albumin (grams per liter) \[g/L\] × -0.0852. ALBI score ≤ -2.60 = ALBI grade 1; -2.60 \< ALBI score ≤ -1.39 = ALBI grade 2 and -1.39 \< ALBI score = ALBI grade 3.

    Time frame: Baseline up to Cycle 42 (1 cycle = 21 days)

  9. Percentage of Participants With Ascites and/or Hepatic Encephalopathy

    Deterioration of hepatic function was monitored by presence of ascites and/or hepatic encephalopathy.

    Time frame: Up to approximately 32 months

07

Results

Posted May 8, 2025

Participant flow

A total of 100 participants took part in the study in Spain from 04 May 2021 to 26 April 2024.

Participant flow — Overall Study
MilestoneAtezolizumab + Bevacizumab
Started100
Intent-to-treat population (itt)99
Completed0
Not completed100
Withdrew: Progressive disease2
Withdrew: Physician decision1
Withdrew: Study terminated by sponsor31
Withdrew: Withdrawal by subject10
Withdrew: Non-compliance with study drug1
Withdrew: Lost to follow-up4
Withdrew: Death51

Outcome measures

PrimaryNumber of Participants Who Discontinued Atezolizumab and/or Bevacizumab Due to Adverse Events (AE) of Grade ≥ 3

AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The severity of AEs was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0) with the following grades: Grade 1 = asymptomatic or mild symptoms; Grade 2 = minimal, local, or non-invasive intervention indicated; Grade 3 = severe or medically significant, but not immediately life-threatening; Grade 4 = life-threatening consequences or urgent intervention indicated and Grade 5 = death related to AE.

Time frame:
From Cycle 1 Day 1 up to 30 days after the final dose of the study drug or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 32 months)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Atezolizumab and/or Bevacizumab Due to Adverse Events (AE) of Grade ≥ 3
ParticipantsAtezolizumab + Bevacizumab
Number of Participants Who Discontinued Atezolizumab and/or Bevacizumab Due to Adverse Events (AE) of Grade ≥ 319
SecondaryOverall Survival (OS)

OS was defined as the time from initiation of study treatment to death from any cause. OS was analyzed using Kaplan-Meier (K-M) methods and Greenwood's formula. Any participant who did not die during the study was censored at the last known date to be alive.

Time frame:
Up to 35 months
Reported as:
Median · months
Overall Survival (OS)
monthsAtezolizumab + Bevacizumab
Overall Survival (OS)24.8 (18.55 to NA)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from initiation of study treatment to the first occurrence of disease progression (PD) or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1). PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm). PFS was analyzed using K-M methods and Greenwood's formula. Any participant who did not experience disease progression or death during the study and were censored at the last known date to be alive or without disease progression.

Time frame:
Up to 35 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsAtezolizumab + Bevacizumab
Progression-free Survival (PFS)9.3 (7.01 to 12.40)
SecondaryObjective Response Rate (ORR)

ORR = percentage of participants with a complete or partial response (CR or PR), on 2 consecutive investigator assessments ≥ 4 weeks apart in participants with measurable disease at baseline as determined by the investigator according to RECIST v1.1. CR = disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to \< 10 mm. PR = at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Participants without a post-baseline tumor assessment were considered non-responders. 95% confidence interval (CI) was derived using Wilson score intervals. Percentages have been rounded off.

Time frame:
Up to 35 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsAtezolizumab + Bevacizumab
Objective Response Rate (ORR)24.2 (16.9 to 33.5)
SecondaryTime to Progression (TTP)

TTP was defined as the time from initiation of study treatment to the first occurrence of PD, as determined by the investigator according to RECIST v1.1. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, SOD must also demonstrate an absolute increase of ≥ 5 mm. TTP was analyzed using K-M methods and Greenwood's formula. Any participant who had no disease progression was censored at the last known date without disease progression.

Time frame:
Up to 35 months
Reported as:
Median · months
Time to Progression (TTP)
monthsAtezolizumab + Bevacizumab
Time to Progression (TTP)11.2 (8.30 to 13.59)
SecondaryDuration of Response (DOR)

DOR was defined as the time from the first occurrence of a documented objective response (CR or PR) to PD or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. DOR was analyzed using K-M methods and Greenwood's formula. Any participant who did not experience disease progression or death during the study was censored at the last known date to be alive or without disease progression.

Time frame:
Up to 35 months
Reported as:
Median · months
Duration of Response (DOR)
monthsAtezolizumab + Bevacizumab
Duration of Response (DOR)15.9 (7.87 to 23.74)
SecondaryPercentage of Participants Who Started Second-line Treatment

Participants who started second-line of treatment were assessed. Percentages have been rounded off.

Time frame:
Up to 35 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Started Second-line Treatment
percentage of participantsAtezolizumab + Bevacizumab
Percentage of Participants Who Started Second-line Treatment24.2
SecondaryChange From Baseline in International Normalized Ratio (INR)

The INR is a standardized measure of the prothrombin time. Blood samples were collected from participants to evaluate coagulation parameters.

Time frame:
Baseline up to Cycle 42 (1 cycle = 21 days)
Reported as:
Mean · INR of prothrombin time
Change From Baseline in International Normalized Ratio (INR)
INR of prothrombin timeAtezolizumab + Bevacizumab
Baseline1.1 ± 0.1
Cycle 420.1 ± 0.0
SecondaryChange From Baseline in Albumin-Bilirubin (ALBI) Score

Blood samples were collected from participants to evaluate of ALBI grades. ALBI assessment grades of 1 to 3 was based on ALBI score calculation. ALBI score= log10 bilirubin (micromole per liter) \[μmol/L\] × 0.66 + albumin (grams per liter) \[g/L\] × -0.0852. ALBI score ≤ -2.60 = ALBI grade 1; -2.60 \< ALBI score ≤ -1.39 = ALBI grade 2 and -1.39 \< ALBI score = ALBI grade 3.

Time frame:
Baseline up to Cycle 42 (1 cycle = 21 days)
Reported as:
Mean · score
Change From Baseline in Albumin-Bilirubin (ALBI) Score
scoreAtezolizumab + Bevacizumab
Baseline-2.7 ± 0.4
Cycle 420.4 ± 0.4
SecondaryPercentage of Participants With Ascites and/or Hepatic Encephalopathy

Deterioration of hepatic function was monitored by presence of ascites and/or hepatic encephalopathy.

Time frame:
Up to approximately 32 months
Reported as:
Number · percentage of participants
Percentage of Participants With Ascites and/or Hepatic Encephalopathy
percentage of participantsAtezolizumab + Bevacizumab
Percentage of Participants With Ascites and/or Hepatic Encephalopathy17

Adverse events

Collected over AEs and SAEs: From Cycle 1 Day 1 up to 30 days after the final dose of the study drug or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 32 months). All cause mortality: Up to 35 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atezolizumab + Bevacizumab:51/100 (51%)46/100 (46%)98/100 (98%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventAtezolizumab + Bevacizumab:
Hepatic EncephalopathyNervous system disorders5/100
Oesophageal Varices HaemorrhageGastrointestinal disorders3/100
AscitesGastrointestinal disorders3/100
Back PainMusculoskeletal and connective tissue disorders3/100
HepatitisHepatobiliary disorders2/100
PyrexiaGeneral disorders2/100
Abdominal PainGastrointestinal disorders2/100
Gastrointestinal HaemorrhageGastrointestinal disorders2/100
Upper Gastrointestinal HaemorrhageGastrointestinal disorders2/100
PneumoniaInfections and infestations2/100
Most frequent other events
Showing 10 of 49
Most frequent other events
EventAtezolizumab + Bevacizumab:
AstheniaGeneral disorders46/100
HypertensionVascular disorders42/100
DiarrhoeaGastrointestinal disorders30/100
PruritusSkin and subcutaneous tissue disorders24/100
Abdominal PainGastrointestinal disorders22/100
Decreased AppetiteMetabolism and nutrition disorders22/100
Covid-19Infections and infestations21/100
ConstipationGastrointestinal disorders20/100
ProteinuriaRenal and urinary disorders18/100
ArthralgiaMusculoskeletal and connective tissue disorders17/100

Baseline characteristics

Safety population included all screened participants (participants who signed the informed consent) who received at least one full or partial dose of study treatment.

Age, Continuous
Age, Continuous(years)Atezolizumab + Bevacizumab
Mean65.4 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Atezolizumab + Bevacizumab
Female13
Male87
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Atezolizumab + Bevacizumab
Hispanic or Latino27
Not Hispanic or Latino73
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atezolizumab + Bevacizumab
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White99
More than one race0
Unknown or Not Reported0
08

Study locations

25 sites
  • Hospital General Universitario de Elche
    Elche, Alicante 03203, Spain
  • Corporacio Sanitaria Parc Tauli
    Sabadell, Barcelona 08208, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Provincial de Castellon
    Castellon de La Plana, Castellon 12002, Spain
  • Hospital Son Llatzer
    Palma de Mallorca, Islas Baleares 07198, Spain
  • Complejo Hospitalario Universitario de Santiago (CHUS)
    Santiago de Compostela, LA Coruna 15706, Spain
  • Hospital de Gran Canaria Dr. Negrin
    Las Palmas de Gran Canaria, LAS Palmas 35010, Spain
  • Hospital Universitario de Torrejon
    Torrejón de Ardoz, Madrid 28850, Spain
  • Clinica Universitaria de Navarra
    Pamplona/iruña, Navarra 31008, Spain
  • Hospital de Basurto
    Bilbao, Vizcaya 48013, Spain
  • Hospital General Univ. de Alicante
    Alicante, 03010, Spain
  • Complejo Hospitalario Torrecardenas
    Almeria, 04009, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial
    Barcelona, 08036, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14004, Spain
  • Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico
    Jaen, 23007, Spain
  • Hospital Lucus Augusti
    Lugo, 27003, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Clinica Universidad de Navarra Madrid
    Madrid, 28027, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Univ. Nuestra Señora de Valme
    Sevilla, 41014, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here ( https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Apr 2024, 35 months.

Results were first posted in May 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 1, 2021
StartActual
May 4, 2021
Primary completionActual
Apr 26, 2024
CompletionActual
Apr 26, 2024
Results first posted
May 8, 2025
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04732286
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 1, 2021
Start date
May 4, 2021
Primary completion
Apr 26, 2024
Completion
Apr 26, 2024
Results posted
May 8, 2025
Last update
May 8, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion